Apremilast (Celgene) Effective in Psoriatic Arthritis

From the American College of Rheumatology…

Apremilast (Celgene), an investigational oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), led to significant improvement in the signs and symptoms of psoriatic arthritis in patients who failed to respond to recommended drugs, including DMARDs and biologics, in the phase 3 PALACE-1 trial.

psoriasisLead investigator Arthur Kavanaugh, from University of California, San Diego, who reported the results, said the drug was “well tolerated and has a good side-effect profile.”

Psoriatic arthritis is a very common type of arthritis and unlike what many physicians think, is not the same as rheumatoid arthritis and must be treated differently.

For more information on arthritis treatments and other arthritis problems,  go to:

Arthritis Treatment

And don’t forget to sign up for  free weekly arthritis tips and a free copy of our special report “The Consumer’s Guide to Arthritis”

Just go here Contact